Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2020-05-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于参加2020年广东辖区上市公司投资者集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor collective reception day event organized by regulatory and industry bodies. It mentions the date and format of the event, and that company executives will communicate with investors about governance, strategy, and operations. The document is short (684 characters) and does not contain financial statements or detailed financial data. It is not a report itself but an announcement related to investor relations and corporate governance communication. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-05-15 Chinese
2020年第一次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening, attendance, voting procedures, and results of a company's 2020 first extraordinary general meeting (临时股东大会). It details the meeting's notice, attendance, voting results on various proposals related to a non-public issuance of A-shares, and confirms the legality and validity of the meeting and its resolutions. The document is not a full annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or a voting results announcement alone, but a legal opinion on the meeting's procedures and results. This type of document is best classified under Regulatory Filings (RNS) as it is a compliance/legal opinion filing related to a shareholder meeting and capital raising proposals, but not the meeting materials themselves or the voting results announcement alone.
2020-05-15 Chinese
2020年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2020 first extraordinary general meeting of shareholders of 特一药业集团股份有限公司. It includes voting results for multiple proposals related to a non-public issuance of A shares, details on meeting attendance, voting methods, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes at a general meeting, including percentages of shares voted for, against, and abstained. There is no indication that this is a full annual or interim report, audit report, or other financial report. The document is not a proxy solicitation or investor presentation but specifically reports the voting results of the shareholder meeting. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (8575 characters) and detailed voting data support this classification with high confidence.
2020-05-15 Chinese
关于提前归还部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the early repayment of part of the temporarily supplemented working capital from raised funds. It discusses the use and repayment of idle raised funds temporarily used for working capital, referencing previous board resolutions and public announcements. The document is short (940 characters) and primarily serves as a disclosure or update on capital usage and repayment, without containing financial statements or detailed financial analysis. This fits the description of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2020-05-12 Chinese
关于控股股东股票质押式回购交易提前购回的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement regarding the early repurchase and release of pledged shares by a controlling shareholder. It details the shareholder's stock pledge transactions and the completion of the pledge release. There is no financial report, earnings data, or management discussion. The content focuses on a specific transaction involving shares and pledges, which fits the category of a Transaction in Own Shares (POS) since it involves the shareholder's stock pledge and repurchase activity. The document length is short and it is not an announcement of a report publication or a certification. Therefore, the best classification is POS.
2020-04-29 Chinese
关于第四届董事会第十二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 12th meeting of the 4th Board of Directors of 特一药业集团股份有限公司. It specifically mentions the approval of the company's 2020 Q1 report and states that the report will be released externally on April 29, 2020. The document itself does not contain the actual financial data or the full quarterly report but is a notice about the board meeting decisions and the upcoming report release. The document length is short (740 characters), and it serves as a formal announcement rather than the report itself. Therefore, it fits best under the category of Board/Management Information (MANG) because it reports on board meeting resolutions, including approval of financial reports, but does not contain the report itself.
2020-04-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.